Skip to main content
PMC home page
Experimental and Therapeutic Medicine logoLink to Experimental and Therapeutic Medicine
. 2017 Mar 24;13(5):2544–2550. doi: 10.3892/etm.2017.4264

Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma

Yu Gong 1,✉, Hongli Yang 1, Xin Tian 2
PMCID: PMC5443281  PMID: 28565877

Abstract

The aim of the present study was to evaluate the expression levels of microRNA (miRNA)-214 in tumor tissue, blood and saliva of patients with gingival carcinoma, and to investigate the mechanisms underlying the infiltration and invasion of gingival carcinoma. Between January 2013 and March 2015, blood and saliva samples, gingival carcinoma tumor specimens and peritumoral tumor tissues were harvested from 56 patients with gingival carcinoma. Blood and saliva samples were also harvested from 33 control patients without gingival carcinoma. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to detect miRNA-214 and protein tyrosine phosphatase gene (PTEN) mRNA levels. Western blotting and ELISA were performed to detect PTEN protein levels. The results of RT-qPCR demonstrated that the expression of PTEN mRNA in tumor tissues, blood and saliva of patients with gingival carcinoma were significantly decreased compared with that of the control group (P<0.05). These findings were consistent were consistent with the results of PTEN protein expression detected via western blotting and ELISA in these samples (P<0.05). Conversely, the expression levels of miRNA-214 in these samples were significantly increased (P<0.05) in patients with gingival carcinoma compared with the control group. The decreased expression of PTEN may be associated with the expression of miRNA-214. miRNA-214 may regulate infiltration and invasion of gingival carcinoma via PTEN. These results suggest that miRNA-214 may be used as a marker of gingival carcinoma.

Keywords: microRNA-214, gingival carcinoma, protein tyrosine phosphatase gene

Introduction

The majority of gingival tumors are highly differentiated squamous cell carcinomas, such as oral squamous cell carcinoma (OSCC) (1). These tumors typically grow slowly and present as ulcers (2). In early stages, tumors are able to infiltrate mandibular alveoli, leading to bone destruction, tooth mobility and pain (1). Surgical therapy is recommended for the treatment for OSCC; however, due to the high degree of malignancy, advanced tumors typically infiltrate surrounding tissues or migrate distantly (3). Migration, which is the leading cause of mortality in patients with gingival carcinoma, occurs in >30% of patients with negative lymph node diagnoses (4). Surgery and chemotherapy are less effective under these circumstances (1). To reduce tumor recurrence and metastasis, and improve survival, >70% of patients have undergone radical treatment which is unnecessary and typically leads to adverse complications, such as severe facial deformities and swallowing, speech, neck and shoulder dysfunction (5–7). Therefore, the identification of accurate diagnostic markers and novel therapeutic targets of gingival carcinoma is necessary.

At present, the activation of oncogenes and mutations of tumor suppressor genes are believed to be the primary mechanisms underlying tumorigenesis (8,9). Similarly, the interactions and coinciding actions of various pathways may result in the tumorigenesis and progression of gingival carcinoma; a process with which various mRNAs and micro (mi)RNAs are associated (10,11). Various recent studies have demonstrated that miRNA-214 is associated with tumorigenesis and progression. For example, Zhang et al (12) showed that miRNA-214 may be used as a diagnostic predictor of gastric tumor and reduce tumor cell proliferation and invasion. Wang et al (13) demonstrated that miRNA-214 was able to modulate the proliferation and invasion of breast cancer via tumour protein p53 (p53). Wang et al (13) reported that miRNA-214 had a suppressive role in bladder cancer via targeting p53 and DNA-damage regulated protein 1 (14). Wan et al (15) demonstrated that miRNA-214 was able to protect cardiomyocytes in follow-up treatment of myocardial ischemia. Izawa et al (16) reported that miRNA-214 may prevent liver fibrosis and effectively relieve liver cirrhosis induced by thioacetamide. These findings suggest that miRNA-214 may be a novel therapeutic agent for cancer prevention, diagnosis and treatment.

Protein tyrosine phosphatase gene (PTEN) belongs to the tumor suppressor gene family. Mutation of PTEN is associated with the development of various human malignancies, and has key roles in apoptosis, cell cycle and cell migration (17–23). In various malignancies, such as prostate cancer (24), brain tumor (6), endometrial cancer (25), glioblastoma (26), melanoma (27), cervical cancer (28), colorectal gland cancer (29), breast cancer (30) and colon cancer (31) PTEN is downregulated. Furthermore, PTEN is associated with gingival carcinoma and its expression is decreased in gingival tumor tissues (10). Another recent study has indicated that PTEN is associated with the occurrence, development and metastasis of gingival carcinoma (32). However, the up-stream regulation factor of PTEN in gingival carcinoma remains to be identified.

In the present study, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blot analysis, gene bioinformatics prediction and ELISA techniques were performed to evaluate the mRNA and protein expression of PTEN and miRNA-214 levels in the tumor tissues, blood and saliva of patients with gingival carcinoma. The association between PTEN and miRNA-214 was subsequently analyzed.

Materials and methods

Research subjects and selection criteria

Between January 2013 and March 2015, blood and saliva samples were harvested from 56 gingival carcinoma patients in the Affiliated Stomatology Hospital of Kunming Medical University (Kunming, China). These patients were diagnosed with gingival carcinoma and chose to receive surgical resection treatment. As a control, blood and saliva samples were harvested from 33 patients from the same hospital diagnosed with non-neoplastic gum disease during the same period. Tumor tissues and peritumoral tissues were subsequently harvested from the 56 gingival carcinoma patients. The gingival carcinoma patients included 38 males and 18 females, aged 17–75 years old, with a median age of 58.6 years. The control patients, included 20 males and 13 females, aged 25–72 years old, with a median age of 59.5 years. All patients were at the early stages of gingival carcinoma or non-neoplastic gum disease and were not treated with hormone therapy, traditional medicine, radiotherapy or chemotherapy prior to surgery. The gingival carcinoma patients included 30 patients with gingival carcinoma in the upper gum and 26 patients with gingival carcinoma in the lower gum, and consisted of one case of mucoepidermoid carcinoma, two cases of adenoid cystic carcinoma, two cases of adenocarcinoma, three cases of myoepithelial carcinoma and 48 cases of squamous cell carcinoma. Prior written and informed consent were obtained from all patients and the study was approved by the ethics review board of Affiliated Stomatology Hospital of Kunming Medical University.

Reagents and instruments

The miRcute miRNA isolation kit (dp501), miRcute miRNA first strand cDNA synthesis kit (KR201), miRcute miRNA fluorescent detection kit (FP 401), SuperReal Premix (SYBR Green) (FP 204) and TIANScript II first strand cDNA synthesis kit (KP 107) were purchased from Tiangen Biotech Co., Ltd. (Beijing, China). The PCR-iQ5 system was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA, USA). The polyclonal rabbit anti-human anti-PTEN antibody (ab32199), mouse monoclonal anti-β-actin antibody (ab6276) and secondary goat anti-rabbit antibody (ab6721) were purchased from Abcam (Cambridge, MA, USA). TRIzol reagent was purchased from Shanghai Yeasen Biotechnology Co., Ltd. (10606ES60; Shanghai, China). The bicinchoninic acid protein assay kit was purchased from Real-Times (Beijing, China) Biotechnology Co., Ltd. (RTP7102; Beijing, China). The miRNeasy serum/plasma kit for serum RNA extraction was purchased from Guangzhou Jianlun Biological Technology Co., Ltd. (JL 217184; Guangzhou, China). The PTEN ELISA kit was purchased from Wuhan USCN Business Co., Ltd. (sE95822Hu; Houston, TX, USA). Image Lab 3.0 software was purchased from Beijing Bio-launching Technologies Co., Ltd. (Beijing, China).

Sample collection

Tumor tissues and peritumoral tissues were preserved in liquid nitrogen for further analysis. Peripheral blood was harvested in the morning following overnight fasting and stored at −20°C following anticoagulation with EDTA.

Prior to saliva collection, research participants were prohibited from food, water and smoking for 2 h to maintain oral hygiene. To increase the quantity of collected saliva, the head of a sterile cotton swab was moistened with 2% citric acid solution, and placed on the first sidewall of tongue for ~5 sec. Following saliva collection, the cotton swab would be applied to the other sidewall. Saliva was collected repeatedly using a sterile enzyme-free centrifuge tube until a total of 5 ml had been harvested.

RT-qPCR

The RT-qPCR was carried out according to the manufacturer's protocol. To detect PTEN, an E.Z.N.A. Total DNA/RNA/Protein kit (Omega Bio-Tek, Inc., Norcross, GA, USA) and TRIzol were used according to the manufacturer's protocol to extract total RNA from samples, and RT was performed to produce cDNA (TIANScript II cDNA kit; Tiangen Biotech Co., Ltd., Beijing, China). The total reaction volume was 20 µl: 10 µl SuperReal Premix (SYBR Green), 0.5 µl upstream primers, 0.5 µl downstream primers, 2 µl cDNA and 7 µl double distilled H2O. Briefly, a 25-µl RT-qPCR system was performed for 40 cycles according to the following conditions: An initial denaturation was performed at 95°C for 3 min, followed by denaturation at 95°C for 12 sec, annealing at 62°C for 40 sec, and extension at 72°C for 20 sec. The results were calculated using 2−ΔΔCq method (33). The PTEN/β-actin ratio was calculated. To detect levels of miRNA-214, RT-qPCR was performed under the same conditions, using U6 as an internal control. The miRNA-214/U6 ratio was calculated. Primers sequences are presented in Table I. Each experiment was repeated three times.

Table I.

Primers used in reverse transcription-quantitative polymerase chain reaction.

Primer Primer sequence
PTEN
  Forward 5′-TTGAAGACCATAACCCACCACAG-3′
  Reverse 5′-CATTACACCAGTTCGTCCCTTTC-3′
β-actin
  Forward 5′-AAGATGACCCAGATCATGTTTGAGACC-3′
  Reverse 5′-GCCAGGTCCAGACGCAGGAT-3′
U6
  Forward 5′-ATTGGAACGATACAGAGAAGATT-3′
  Reverse 5′-GGAACGCTTCACGAATTTG-3′
miR-214
  Forward 5′-AGCATAATACAGCAGGCACAGAC-3′
  Reverse 5′-AAAGGTTGTTCTCCACTCTCTCAC-3′
Open in a new tab

PTEN, protein tyrosine phosphatase gene; miR, microRNA.

Western blot analysis

Total proteins were extracted and separated by 10% SDS-PAGE and transferred onto a nitrocellulose membrane. Following blocking with non-fat milk, the membrane was incubated with primary anti-PTEN (1:500) and anti-β-actin (1:5,000) antibodies at 4°C overnight. The membrane was subsequently washed with TBST 5 times for 5 min. Following washing, the membrane was incubated with goat anti-rabbit secondary antibody (1:3,000) at room temperature for 1 h. The membrane was subsequently developed using enhanced chemiluminescence plus an enhanced chemiluminescence reagent (BeyonECL Plus; Beyotime Institute of Biotechnology, Haimen, China). Image lab 3.0 software was used to analyze results. β-actin was used as an internal control. The relative expression level of PTEN was calculated based on the expression of β-actin.

ELISA

Blood samples were centrifuged at 1,000 × g for 10 min at 4°C to separate serum and red blood cells. ELISA was performed according to the manufacturer's protocol of the PTEN ELISA kit. Briefly, blank wells and wells for standard sample, serum and saliva were prepared. In the wells for standard sample, 50-µl standard samples with different concentrations (180, 120, 60, 30, 15, 7.5 and 3.75 pg/ml) were added. In the wells for serum and saliva, 10 µl serum or saliva and 40 µl dilution solution were added. Nothing was added to blank wells. Besides blank wells, 100 µl horseradish peroxidase-labeled detection antibody (1:1,000) mixed with dilution buffer was added to each well. The plate was sealed and incubated for 1 h at room temperature. Following five repeated washes with the provided washing buffer, the substrate (50 µl substrate A and 50 µl substrate B) was added to each well and incubated for 15 min at 37°C. The reaction was terminated by adding 50 µl stopping solution to each well. Optical density was measured at a wavelength of 450 nm.

Bioinformatics prediction

Bioinformatics prediction is currently the recommended technique for the study of miRNA function (34). In order to evaluate the regulation mechanism of PTEN, miRanda (www.microma.org/rnicroma/home.do), TargetScan (www.targetscan.org), PiTa (www.genie.weizmann.ac.il/pubs/mir07), RNAhybrid (www.hibiserv.techfak.uni-bielefeld.de/rnahybrid) and Pictar (www.pictar.mdc-berlin.de) programs were used to predict the possible regulatory gene of PTEN.

Statistical analysis

Data were processed using SPSS, version 18.0 (SPSS, Inc., Chicago, IL, USA). Data are presented as the mean ± standard deviation. The normality of data was tested using the Kolmogorov-Smirnov test. Comparison among multiple sets of measurement data was performed using one-way analysis of variance. When there was homogeneity of variance, least significant difference and Student-Newman-Keuls tests were performed. Otherwise, Tamhane's T2 or Dunnett's T3 method was used. P<0.05 was considered to indicate a statistically significant difference.

Results

Level of PTEN mRNA in samples

miRNA-214 was identified as one of the genes that may regulate PTEN (Fig. 1). RT-qPCR was performed to detect levels of PTEN mRNA in tumor tissues, peritumoral tissues, blood and saliva. Compared with that in peritumoral tissues, PTEN mRNA levels in tumor tissues of patients with gingival carcinoma was significantly lower (P<0.05; Fig. 2A). Similarly, compared with those observed in control patients, PTEN mRNA levels in the blood and saliva of gingival carcinoma patients were significantly decreased (both P<0.05; Fig. 2B and C). These results indicate that PTEN may have a role in gingival carcinoma.

Figure 1.

Figure 1.

Open in a new tab

Prediction of the upstream regulatory gene of PTEN. Using miRanda, TargetScan, PiTa, PicTar, and BibiServ, miRNA-214 was predicted as a regulatory gene of PTEN. PTEN, protein tyrosine phosphatase gene; miRNA/miR, microRNA.

Figure 2.

Figure 2.

Open in a new tab

Analysis of PTEN mRNA expression levels. PTEN mRNA expression levels were detected via reverse transcription-quantitative polymerase chain reaction. (A) Expression level of PTEN mRNA in tumor and peritumoral tissues of patients with gingival carcinoma. (B) Expression level of PTEN mRNA in blood of patients with gingival carcinoma and control patients. (C) Expression level of PTEN mRNA in saliva of patients with gingival carcinoma and control patients. *P<0.05 and **P<0.01. PTEN, protein tyrosine phosphatase gene.

Protein expression level of PTEN in tumor and peritumoral tissues

Western blotting was performed to determine the expression level of PTEN in tumor and peritumoral tissues. As demonstrated in Fig. 3, in gingival carcinoma patients, the PTEN protein level in the tumor tissues was significantly decreased compared with that in peritumoral tissues (P<0.05). This finding was consistent with that observed in PTEN mRNA levels, which suggests that PTEN is downregulated at the transcriptional and protein expression level and that this downregulation may have a role in gingival carcinoma.

Figure 3.

Figure 3.

Open in a new tab

Analysis of PTEN protein expression level in tumor and peritumoral tissues. PTEN protein expression level was detected via western blotting. (A) Representative and (B) quantitative western blot results were presented. **P<0.01 vs. peritumoral tissues. PTEN, protein tyrosine phosphatase gene.

Protein expression level of PTEN in blood and saliva

The expression level of PTEN protein in blood and saliva was detected via ELISA. Compared with control patients, the expression level of PTEN was significantly decreased in the blood (P<0.05; Fig. 4A) and saliva (P<0.01; Fig. 4B) of gingival carcinoma patients. These results were consistent with those observed in PTEN mRNA. As blood is a typical channel of gingival carcinoma metastasis (35), the decrease of PTEN protein in blood may be associated with gingival carcinoma metastasis. Furthermore, the downregulation of PTEN protein level in saliva may be a potential marker of gingival carcinoma.

Figure 4.

Figure 4.

Open in a new tab

Analysis of PTEN protein expression level in blood and saliva. PTEN protein expression level in blood and saliva was detected using ELISA. (A) Expression level of PTEN protein in blood of patients with gingival carcinoma and control patients. (B) Expression level of PTEN in saliva of patients with gingival carcinoma and control patients. *P<0.05 and **P<0.01 vs. control patients. PTEN, protein tyrosine phosphatase gene.

Expression level of miRNA-214 in tumor tissues, peritumoral tissues, blood and saliva

RT-qPCR was performed to detect expression levels of miRNA-214 in tumor tissues, peritumoral tissues, blood and saliva. As presented in Fig. 5A, miRNA-214 level in the tumor tissues of gingival carcinoma patients was significantly higher than that in peritumoral tissues of gingival carcinoma patients (P<0.01). Similarly, miRNA-214 levels in the blood (Fig. 5B) and saliva (Fig. 5C) of gingival carcinoma patients were significantly increased in comparison with those in control patients (both P<0.01). In combination with the finding that miRNA-214 may be a regulatory gene PTEN, these results suggest that miRNA-214 may have a regulatory effect on gingival carcinoma, and it may regulate the transcriptional level of PTEN and ultimately affect the protein level of PTEN.

Figure 5.

Figure 5.

Open in a new tab

Analysis of miRNA-214 levels. Levels of miRNA-214 were detected via reverse transcription-quantitative polymerase chain reaction. (A) Expression level of miRNA-214 in tumor and peritumoral tissues of patients with gingival carcinoma. (B) Expression level of miRNA-214 in blood of patients with gingival carcinoma and control patients. (C) Expression of miRNA-214 in saliva of patients with gingival carcinoma and control patients. **P<0.01. miRNA, microRNA.

Discussion

In the present study, the mRNA and protein levels of PTEN in tumor tissues, peritumoral tissues, blood and saliva of patients with gingival carcinoma were evaluated. The expression of miRNA-214, a predicted upstream gene of PTEN, was detected simultaneously, and the potential regulation of PTEN by miRNA-214 in gingival carcinoma was identified.

Among oral and maxillofacial malignancies, >80% of tumors are OSCC, and is the sixth most prevalent carcinoma worldwide (36,37). OSCC typically occurs in the tongue, gingiva, and cheek (38). It is clinically characterized by a high degree of malignancy, trend toward regional lymph node metastasis and poor prognosis (2). The majority of advanced OSCCs exhibit invasive growth (39), and it is difficult to surgically remove tumors that have infiltrated surrounding tissues and migrated distantly, and traditional chemotherapy has been demonstrated to have a low efficacy in this scenario (40). The improvement of early diagnosis and the implementation of individualized treatment has become necessary to ameliorate the treatment efficacy and prognosis of OSCC (41). Therefore, there is a need to clarify the pathogenesis of OSCC with surrounding tissue infiltration and distant metastasis and to identify novel gene targets for therapy.

As a tumor suppressor gene, PTEN was discovered in 1997 and is located on chromosome 10 (10q 23.3) (25,42,43). The downregulation or deletion of PTEN has a role in apoptosis, cell cycle and cell migration, and is associated with the development of various human malignancies (44).

Previous research on the effect of PTEN on tumorigenesis has predominantly focused on endometrial cancer, glioma, prostate cancer, breast cancer and melanoma (25–31). However, to the best of our knowledge, the role of PTEN in OSCC has been rarely reported. Although the mechanism remains to be elucidated, an abnormal decrease of PTEN has been demonstrated in the majority of types of tumor (6,25–31). In the present study, a significant reduction in PTEN expression was observed in the tumor tissues, blood and saliva of patients with gingival carcinoma compared with control patients. As tumors may migrate through blood as well as via regional invasion, the reduction of PTEN in the blood of patients with gingival carcinoma suggests that PTEN may have a role in tumor metastasis. It is possible that a reduction in PTEN reduces apoptosis, whereas excessive proliferation of cells is associated with increased cell infiltration and mitigation, leading to tumor metastasis. Additionally, changes in PTEN levels in the blood and saliva of patients may be a potential biomarker of gingival carcinoma, particularly in the early stage of tumorigenesis.

Bioinformatics were applied to predict possible upstream regulatory genes of PTEN. It has recently been demonstrated that a class of small, endogenous and non-coding nucleic acid miRNAs are able to prevent transcription of PTEN mRNA (45). According to the current literature, miRNAs have a high level of stability in conventional, formalin-fixed, paraffin-embedded clinical tissue specimens, which suggests that they may have potential as diagnostic molecular markers; however, mRNAs tend to be more susceptible to environmental impact and are more unstable than miRNAs (46–48). Furthermore, it has previously been suggested that miRNAs serve important roles in tumorigenesis via their regulation of protein coding genes (49,50). The cleavage of PTEN mRNA may lead to downregulation of PTEN protein. As predicted, miRNA-214 was shown to be closely associated with PTEN; therefore it may be an upstream regulatory gene of PTEN. Furthermore, it has previously been demonstrated that miRNA-214 is able to regulate PTEN in the processes of tumor invasion and metastasis in human gastric cancer, breast cancer and cervical cancer (51–53).

In the present study, a significant increase of miRNA-214 levels was observed in the tumor tissues, blood and saliva of patients with gingival carcinoma. These results suggest that PTEN in gingival carcinoma is directly downregulated by miRNA-214, as the upregulation of miRNA-214 may promote cleavage of PTEN, thus inhibiting the proapoptotic effect of PTEN protein, the formation of gingival cysts and ultimately gingival tumorigenesis.

In conclusion, the balance between miRNA-214 and PTEN levels may regulate the tumorigenesis and progression of gingival carcinoma. Additionally, miRNA-214 is more stable than PTEN in blood and saliva, and may be a more suitable marker for the early diagnosis of gingival carcinoma.

Acknowledgements

The authors of the present study want to thank Dr Shenglan Wang from the Oncology Department of the First People's Hospital of Yunnan Province (Kunming, China).

References

  • 1.Qiu W. Oral and maxillofacial surgery. 6th. People's Medical Publishing House; Beijing: 2008. pp. 274–275. [Google Scholar]
  • 2.Girdler NM. Oral ulceration: Benign or malignant? A diagnostic dilemma. Br Dent J. 1990;168:386. doi: 10.1038/sj.bdj.4807207. [DOI] [PubMed] [Google Scholar]
  • 3.Ferlito A, Shaha AR, Rinaldo A. The incidence of lymph node micrometastases in patients pathologically staged No in cancer of oral cavity and oropharynx. Oral Oncol. 2002;38:3–5. doi: 10.1016/S1368-8375(01)00037-9. [DOI] [PubMed] [Google Scholar]
  • 4.Kademani D. Oral cancer. Mayo Clin Proc. 2007;82:878–887. doi: 10.4065/82.7.878. [DOI] [PubMed] [Google Scholar]
  • 5.Becker MT, Shores CG, Yu KK, Yarbrough WG. Molecular assay to detect metastatic head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130:21–27. doi: 10.1001/archotol.130.1.21. [DOI] [PubMed] [Google Scholar]
  • 6.Németh Z, Velich N, Bogdan S, Ujpál M, Szabó G, Suba ZS. The prognostic role of clinical, morphological and molecular markers in oral squamous cell tumors. Neoplasma. 2005;52:95–102. [PubMed] [Google Scholar]
  • 7.He H, Huang J, Ping F, Chen G, Zhang S, Dong Y. Anatomical and clinical study of lingual arterial chemoembolization for tongue carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:e1–e5. doi: 10.1016/j.tripleo.2006.11.019. [DOI] [PubMed] [Google Scholar]
  • 8.Mano H. Discovery and clinical application of mutations in the cancer genome. Nihon Rinsho. 2015;73:1251–1255. (In Japanese) [PubMed] [Google Scholar]
  • 9.Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing and human cancer. J Clin Med. 2015;4:1651–1667. doi: 10.3390/jcm4081651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Li JD, Liang RY, Zhao YP, Xu YL. Correlation analysis of VEGF and PTEN expression in gingival carcinoma. Shanghai Kou Qiang Yi Xue. 2014;23:619–623. (In Chinese) [PubMed] [Google Scholar]
  • 11.Boldrup L, Coates PJ, Wahlgren M, Laurell G, Nylander K. Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins. J Carcinog. 2012;11:18. doi: 10.4103/1477-3163.104007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhang KC, Xi HQ, Cui JX, Shen WS, Li JY, Wei B, Chen L. Hemolysis-free plasma miR-214 as novel biomarker of gastric cancer and is correlated with distant metastasis. Am J Cancer Res. 2015;5:821–829. [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang F, Lv P, Liu X, Zhu M, Qiu X. microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53. Int J Mol Med. 2015;35:1395–1402. doi: 10.3892/ijmm.2015.2123. [DOI] [PubMed] [Google Scholar]
  • 14.Wang J, Zhang X, Wang L, Yang Y, Dong Z, Wang H, Du L, Wang C. MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer. PLoS One. 2015;10:e0118086. doi: 10.1371/journal.pone.0118086. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 15.Wan DY, Zhang Z, Yang HH. Cardioprotective effect of miR-214 in myocardial ischemic postconditioning by down-regulation of hypoxia inducible factor 1, alpha subunit inhibitor. Cell Mol Biol (Noisy-le-grand) 2015;61:1–6. [PubMed] [Google Scholar]
  • 16.Izawa T, Horiuchi T, Atarashi M, Kuwamura M, Yamate J. Anti-fibrotic role of miR-214 in Thioacetamide-induced liver cirrhosis in rats. Toxicol Pathol. 2015;43:844–851. doi: 10.1177/0192623315573587. [DOI] [PubMed] [Google Scholar]
  • 17.Squarize CH, Castilho RM, Santos Pinto D., Jr Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system. J Oral Pathol Med. 2002;31:379–384. doi: 10.1034/j.1600-0714.2002.00142.x. [DOI] [PubMed] [Google Scholar]
  • 18.Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA. 1998;95:15406–15411. doi: 10.1073/pnas.95.26.15406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387–390. doi: 10.1016/S0092-8674(00)80674-1. [DOI] [PubMed] [Google Scholar]
  • 20.Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R, Liu X, Wu H. Essential role of AKT-1/protein kinase B in PTEN-controlled tumorigenesis. Mol Cell Biol. 2002;22:3842–3851. doi: 10.1128/MCB.22.11.3842-3851.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN1. Cancer Res. 1999;59:2551–2556. [PubMed] [Google Scholar]
  • 22.Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 1999;59:442–449. [PubMed] [Google Scholar]
  • 23.McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249–279. doi: 10.1016/j.advenzreg.2006.01.004. [DOI] [PubMed] [Google Scholar]
  • 24.Punnoose EA, Ferraldeschi R, Szafer-Glusman E, Tucker EK, Mohan S, Flohr P, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN, et al. PTEN loss in circulating tumor cells correlates with PTEN loss in fresh tumor tissue from castration-resistant prostate cancer patients. Br J Cancer. 2015;113:1225–1233. doi: 10.1038/bjc.2015.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  • 26.Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924–930. doi: 10.1093/jnci/92.11.924. [DOI] [PubMed] [Google Scholar]
  • 27.Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene. 1998;16:2259–2264. doi: 10.1038/sj.onc.1201756. [DOI] [PubMed] [Google Scholar]
  • 28.Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene. 1998;16:3397–3402. doi: 10.1038/sj.onc.1201881. [DOI] [PubMed] [Google Scholar]
  • 29.Rizvi MM, Alam MS, Ali A, Mehdi SJ, Batra S, Mandal AK. Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol. 2011;137:1255–1262. doi: 10.1007/s00432-011-0994-0. [DOI] [PubMed] [Google Scholar]
  • 30.Yang XF, Xin Y, Mao LL. Clinicopathological significance of PTEN and caspase-3 expressions in breast cancer. Chin Med Sci J. 2008;23:95–102. doi: 10.1016/S1001-9294(09)60019-5. [DOI] [PubMed] [Google Scholar]
  • 31.Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhou Y, Rychahou PG, Evers BM. PTEN loss induces epithelial-mesenchymal transition in human colon cancer cells. Anticancer Res. 2009;29:4439–4449. [PMC free article] [PubMed] [Google Scholar]
  • 32.Ren W, Qiang C, Gao L, Li SM, Zhang LM, Wang XL, Dong JW, Chen C, Liu CY, Zhi KQ. Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are promising novel biomarkers for detection of oral squamous cell carcinoma. Biomarkers. 2014;19:590–596. doi: 10.3109/1354750X.2014.955059. [DOI] [PubMed] [Google Scholar]
  • 33.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-tie quantitative PCR and the 2(−Delta Delta C (T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 34.León LE, Calligaris SD. Visualization and analysis of MiRNA-targets interactions networks. Methods Mol Biol. 2017;1509:209–220. doi: 10.1007/978-1-4939-6524-3_19. [DOI] [PubMed] [Google Scholar]
  • 35.Falconieri G, Luna MA, Pizzolitto S, DeMaglio G, Angione V, Rocco M. Eosinophil-rich squamous carcinoma of the oral cavity: A study of 13 cases and delineation of a possible new microscopic entity. Ann Diagn Pathol. 2008;12:322–327. doi: 10.1016/j.anndiagpath.2008.02.008. [DOI] [PubMed] [Google Scholar]
  • 36.Kalnins IK, Leonard AG, Sako K, Razack MS, Shedd DP. Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity. Am J Surg. 1977;134:450–454. doi: 10.1016/0002-9610(77)90376-2. [DOI] [PubMed] [Google Scholar]
  • 37.Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156. doi: 10.1002/ijc.1440. [DOI] [PubMed] [Google Scholar]
  • 38.Rautava J, Luukkaa M, Heikinheimo K, Alin J, Grenman R, Happonen RP. Squamous cell carcinomas arising from different types of oral epithelia differ in their tumor and patient characteristics and survival. Oral Oncol. 2007;43:911–919. doi: 10.1016/j.oraloncology.2006.11.012. [DOI] [PubMed] [Google Scholar]
  • 39.Yoshida R, Nakayama H, Nagata M, Hirosue A, Tanaka T, Kawahara K, Nakagawa Y, Matsuoka Y, Sakata J, Arita H, et al. Overexpression of nucleostemin contributes to an advanced malignant phenotype and a poor prognosis in oral squamous cell carcinoma. Br J Cancer. 2014;111:2308–2315. doi: 10.1038/bjc.2014.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kirita T, Yamanaka Y, Imai Y, Yamakawa N, Aoki K, Nakagawa Y, Yagyuu T, Hasegawa M. Preoperative concurrent chemoradiotherapy for stages II–IV oral squamous cell carcinoma: A retrospective analysis and the future possibility of this treatment strategy. Int J Oral Maxillofac Surg. 2012;41:421–428. doi: 10.1016/j.ijom.2011.12.003. [DOI] [PubMed] [Google Scholar]
  • 41.Cheng YS, Rees T, Wright J. A review of research on salivary biomarkers for oral cancer detection. Clin Transl Med. 2014;3:3. doi: 10.1186/2001-1326-3-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  • 43.Li DM, Sun H. PTEN, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997;57:2124–2129. [PubMed] [Google Scholar]
  • 44.Wang YF, Tang WP. Progress of PTEN gene and oral and maxillofacial tumors. Shi Yong Lin Chuang Yi Xue. 2010;11:125–127. [Google Scholar]
  • 45.Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z, Liu Y. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN. Oncol Rep. 2015;34:1003–1010. doi: 10.3892/or.2015.4030. [DOI] [PubMed] [Google Scholar]
  • 46.Howe K. Extraction of miRNAs from formalin-fixed paraffin-embedded (FFPE) tissues. Methods Mol Biol. 2017;1509:17–24. doi: 10.1007/978-1-4939-6524-3_3. [DOI] [PubMed] [Google Scholar]
  • 47.Deng H, Liu Q, Wang X, Huang R, Liu H, Lin Q, Zhou X, Xing D. Quantum dots-labeled strip biosensor for rapid and sensitive detection of microRNA based on target-recycled nonenzymatic amplification strategy. Biosens Bioelectron. 2017;87:931–940. doi: 10.1016/j.bios.2016.09.043. [DOI] [PubMed] [Google Scholar]
  • 48.Rissland OS. The organization and regulation of mRNA-protein complexes. Wiley Interdiscip Rev RNA. 2017;8 doi: 10.1002/wrna.1369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8:93–103. doi: 10.1038/nrg1990. [DOI] [PubMed] [Google Scholar]
  • 50.Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20. doi: 10.1016/j.cell.2004.12.035. [DOI] [PubMed] [Google Scholar]
  • 51.Yang TS, Yang XH, Wang XD, Wang YL, Zhou B, Song ZS. MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int. 2013;13:68. doi: 10.1186/1475-2867-13-68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V, Pantel K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat. 2012;134:933–941. doi: 10.1007/s10549-012-1988-6. [DOI] [PubMed] [Google Scholar]
  • 53.Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–433. doi: 10.1158/0008-5472.CAN-07-6426. [DOI] [PubMed] [Google Scholar]

Articles from Experimental and Therapeutic Medicine are provided here courtesy of Spandidos Publications

RESOURCES